MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.28 -0.78

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.28

Máximo

1.34

Métricas clave
By Trading Economics
Ingresos	2.7M -24M
BPA	-0.354
Empleados	49
EBITDA	-5.3M -28M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+105.38% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-5K 81M
Apertura anterior	2.06
Cierre anterior	1.28

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 abr 2026, 23:25 UTC

Noticias de Eventos Importantes

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 abr 2026, 22:45 UTC

Noticias de Eventos Importantes

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 abr 2026, 18:03 UTC

Ganancias

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 abr 2026, 23:58 UTC

Ganancias

Review & Preview: Earnings Time -- Barrons.com

13 abr 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 abr 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 abr 2026, 23:20 UTC

Charlas de Mercado

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 abr 2026, 23:01 UTC

Ganancias

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 abr 2026, 23:01 UTC

Ganancias

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 abr 2026, 23:01 UTC

Ganancias

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 abr 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 abr 2026, 21:26 UTC

Noticias de Eventos Importantes

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 abr 2026, 21:23 UTC

Ganancias

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 abr 2026, 21:16 UTC

Ganancias

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 abr 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

13 abr 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

13 abr 2026, 20:34 UTC

Ganancias

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 abr 2026, 20:34 UTC

Ganancias

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 abr 2026, 20:34 UTC

Ganancias

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 abr 2026, 19:59 UTC

Charlas de Mercado

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 abr 2026, 19:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 abr 2026, 19:27 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Correction to Precious Metals Market Talk on April 9

13 abr 2026, 19:14 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 abr 2026, 18:59 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 abr 2026, 18:59 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 abr 2026, 18:43 UTC

Charlas de Mercado

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

105.38% repunte

Estimación a 12 Meses

Media 2.67 USD 105.38%

Máximo 3 USD

Mínimo 2 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.